Issue Price
₹128
Per Share
GMP
NIL
Grey Market
Est. Listing
₹128
Expected Price
Min. Application
₹256,000
2 lots × 1000 shares
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.Products:General pharmaceutical tablets and capsulesOral liquidsExternal preparationsSterile ophthalmic ointmentsThe company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.As of July 31, 2025, the company has 95 permanent employees.Competitive Strengths:Experienced Promoters and Management TeamWide range of ProductsStrategic Location of Manufacturing FacilityScalable Business ModelQuality assurance
Curis Lifesciences Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| Market Maker | 108,000 | — | ₹1.38 Cr | — |
| TOTAL | 2,150,000 | 100.00% | ₹27.52 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹128,000 |
| Retail (Max) | 13 | 13,000 | ₹1,664,000 |
| sNII (Min) | 14 | 14,000 | ₹1,792,000 |
| bNII (Min) | 68 | 68,000 | ₹8,704,000 |
| Particulars | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue from Operations | 19.51 | 49.65 | 35.87 |
| EBITDA | 4.24 | 9.54 | 8.39 |
| Profit After Tax (PAT) | 2.87 | 6.11 | 4.87 |
| Net Worth | 19.10 | 16.23 | 5.87 |
| Total Assets | 56.29 | 42.53 | 33.88 |
| Reserves & Surplus | 13.16 | 10.29 | 5.37 |
| Total Borrowings | 15.32 | 15.62 | 17.09 |